Two months after Merck’s pneumococcal vaccine candidate V116 won breakthrough therapy designation based on Phase I/II trial data, Merck is now starting to share data from that study — touting topline results as the Big Pharma pushes to Phase III clinical trials.
Merck reported Tuesday that V116 showed non-inferior and superior immune responses, depending on the serotype, in hundreds of adult patients in the Phase II portion of the study. For shared serotypes with Merck’s older vaccine, Pneumovax 23, the responses were non-inferior. But for those not in the older shot, responses were superior, Merck said.
The company unveiled results of its trial at the ISPPD (International Society of Pneumonia and Pneumococcal Diseases) annual conference in Toronto on Monday afternoon after Heather Platt, one of Merck’s clinical researchers, sat down with Endpoints News and explained the data.
Platt, a clinical director, had been working on the candidate for 4.5 years….
Click here to view original post
